The Management Board of Vienna-based VelaLabs GmbH will expand in order to adapt to the current challenges.
Dr. Markus Fido, co-founder and CEO of VelaLabs until 2019, will devote himself to his new tasks within Tentamus Pharma and take over the global coordination of the Pharma projects as a Director Business Development International.
DI (FH) Markus Roucka is assigned as Managing Director of VelaLabs effective immediately.
DI (FH) Klaus Hajszan will take over the responsibilities of Dr. Markus Fido in the Management Board.
Dr. Markus Fido had a pivotal role in the successful growth and recognition of VelaLabs GmbH. He will now occupy a superior position as Director Business Development International and take over the coordination of global pharmaceutical projects in the parent company Tentamus Pharma. The aim of this position is to manage the communication of the Tentamus Pharma laboratories in order to bring integrated services to the customer.
We would like to use this opportunity and thank Dr. Fido for building and leading VelaLabs throughout the years.
The Management Board, which represents the operative leadership of the company, was prepared half a year ago as a new strategic top management and currently consists of the following people:
Klaus Hajszan has been part of the company since 2007 and has occupied multiple positions related to quality management. As part of the Management Board, he will be responsible for adherence to and continuous improvement of the quality processes. Additionally, he is employed by the company as an independent Qualified Person.
Albert Lauss started his career in 1990 at Immuno AG in Vienna, fulfilling different quality-related functions. Since April 2018, he has been part of the management at VelaLabs GmbH. As a member of the Management Board, he is responsible for finances, personnel and operations.
Markus Roucka has been in the company since 2008, beginning as a senior lab technician in the Quality Control. In 2016, he took over the position of a COO where he managed the laboratory operations. His responsibilities in the Management Board involve customer relations, customer acquisition, marketing, and project management.
VelaLabs GmbH
VelaLabs was founded in 2006 in the former Novartis Campus in Vienna. Since 2007, it is a GMP-certified service-oriented company with focus on analytical and quality control of biopharmaceutical products, as well as clinical development of biosimilars, biologics and ATMPs. By the acquisition of LABH in 2019, VelaLabs can now also offer all types of microbiological services. Together with its strong team, the VelaLabs Management aims to successfully realize its vision of the future and expand its base of operations.
Among the new goals are digitalization and expansion of its analytical method portfolio for innovative products, as well as GLP certification and ISO 17025 accreditation.
Tentamus Group GmbH was founded in 2011. Tentamus is a global product and safety group with a core presence in Europe, UK, Israel, China, Japan, India and the USA. Accredited and licensed Tentamus Group tests, audits and consults on all products involving the human body (food & feed, pharmaceuticals & medical, agrosciences, cosmetics, agriculture & environment and nutraceutical & supplements). Tentamus Group is represented in over 65 locations worldwide. More than 2,500 highly-trained staff members work in over 2.5 million square feet of laboratory and office spaces. For further information please visit www.tentamus.com.
Tentamus Group GmbH
An der Industriebahn 26
13088 Berlin
Telefon: +49 (30) 206038-230
Telefax: +49 (30) 206038-190
http://www.tentamus.com
Telefon: +43 (0)1 890 5979 11
E-Mail: management@vela-labs.at
